Show results for
Refine by
Stem Cell Based Articles & Analysis
28 news found
” Ace Therapeutics’ gene therapy development services for glaucoma offer comprehensive solutions that include stem cell-based gene therapy development, siRNA development, gene delivery system engineering, and preclinical testing. Based on years of CRO experience, Ace Therapeutics' integrated development pipeline ...
In this free webinar, learn about the challenges in maintaining reliability, reproducibility and consistency in induced pluripotent stem cell (iPSC) cultures. Attendees will be introduced to a novel cell line restoration method supported by high-throughput single-cell cloning technologies. The featured speakers will explore the ...
Stem cell therapy is a groundbreaking field in the pharmaceutical industry, offering powerful tools for treating severe diseases such as cancer. The genetic manipulations involved in this process, however, necessitate stringent regulations to ensure sterility and safety. In 2017, the Food and Drug Administration (FDA) took significant steps towards regulating stem cell therapy, marking a pivotal ...
” A leader in contract research, development and manufacturing of human-induced pluripotent stem cell-based solutions (iPSC), Ncardia’s capabilities include bio-reactor-based scalable manufacturing of iPSC derived cells, assay development, disease modeling, and ...
(NASDAQ: ORGS) (“Orgenesis” or the “Company”), a global biotech company working to unlock the full potential of cell and gene therapies, and Kurve Therapeutics, a next-generation medtech and drug formulation company, today announced positive preclinical study results for intranasal administration of a cell-based oncolytic ...
Development of a safer stem cell-based diabetes therapy via suicide gene-mediated ablation of proliferative cells. Evaluation of a beta cell replacement therapy combined product that avoids the need for immunosuppression via localized induction of immune ...
TreeFrog Therapeutics, a biotechnology company aimed at making safer, more efficient and more affordable cell therapies based on induced pluripotent stem cells (iPSCs), today announced the launch of The Stem Cell SpaceShot Grant, a $100,000 research funding in the field of stem ...
TreeFrog Therapeutics, a biotechnology company aimed at making safer, more efficient and more affordable cell therapies based on induced pluripotent stem cells (iPSCs), today announced the appointment of new independent members to its board: Elsy Boglioli, former Chief Operating Officer at Cellectis, Founder and Chief Executive ...
TreeFrog Therapeutics, a French-based biotech company aimed at making safer, more efficient and more affordable cell therapies based on induced pluripotent stem cells (iPSCs), today announced the incorporation of its Japanese subsidiary (KK) TreeFrog Therapeutics Japan and the establishment of a lab in Kobe, at ...
U.S. Stem Cell, Inc. (OTC: USRM), a leader in the development of proprietary, physician-based stem cell therapies and novel regenerative medicine solutions has appointed Mark Borman as Chairman of the Board as Dr. ...
Now bringing over 70 biophysicists, stem cell biologists and bioproduction engineers, TreeFrog Therapeutics raised $82M over the past 3 years to advance its pipeline of stem cell-based therapies in the field of neurodegeneration, cardio-metabolic disorders, and immuno-oncology. ...
“The decision by the AMA to issue these new CPT® codes is a major milestone for InGeneron and advances the potential of innovative and evidence-based stem cell therapies,” said InGeneron Executive Chairman Eckhard Alt, MD PhD. “The issuance of these CPT® codes marks an important step toward providing patients with the ...
Priest led the investigational new drug (IND)-enabling work required to generate compelling preclinical safety and efficacy data for NRTX-1001, applying her significant experience in the translational development of stem cell-based medicines, relevant model systems, and regulatory guidelines. ...
U.S. Stem Cell, Inc. (OTC: USRM), a leader in the development of proprietary, physician-based stem cell therapies and novel regenerative medicine solutions will take steps to relaunch its veterinary division to tackle animal health innovation. ...
Fast forward to today, regenerative medicine is regarded as a major advancement in medical treatment, based on the principles of stem cell technology and tissue engineering, designed to replace or regenerate human tissues and organs and restore their functions. ...
Modena, September 20, 2019 – During EUROPEAN BIOTECH WEEK and EMILIA-ROMAGNA OPEN Event, Friday 27 September 2019 Holostem will open its doors to the city with two events: Open Day from 15:00 to 17:00 for the discovery of stem cells and their clinical application for the treatment of rare diseases without therapeutic alternatives. Citizens will be able to ...
U.S. Stem Cell, Inc. (OTC: USRM), a leader in the development of proprietary, physician-based stem cell therapies and novel regenerative medicine solutions, today announced earnings for the second quarter that ended June 30, 2019. ...
U.S. Stem Cell, Inc. (OTC: USRM), a leader in the development of proprietary, physician-based stem cell therapies and novel regenerative medicine solutions, today announced earnings for the second quarter that ended June 30, 2019. ...
U.S. Stem Cell, Inc. (OTC: USRM), a leader in the development of proprietary, physician-based stem cell therapies and novel regenerative medicine solutions, today announced financial results for the first quarter ended March 31, 2019. ...
U.S. Stem Cell, Inc. (OTC: USRM), a leader in the development of proprietary, physician-based stem cell therapies and novel regenerative medicine solutions, today announced positive financial results for the year ended December 31, 2018. ...